We seek a global understanding of the molecular factors controlling cancer progression and anti-tumor immunity. Towards this end, we utilize a diverse set of modern tools including high-throughput screening, in vivo CRISPR genome editing, animal models, synthetic biology, and bioinformatics. Our goal is to uncover novel insights in cancer and develop them into the next generation of therapeutics.
Our research is supported by:
-National Institutes of Health
-National Cancer Institute
-The Mary Kay Foundation
-Ludwig Family Foundation
-Melanoma Research Alliance
-St. Baldrick’s Foundation
-Breast Cancer Alliance
-Alliance for Cancer Gene Therapy
-Blavatnik Family Foundation
-Yale Cancer Center
-Cancer Research Institute
-AACR
-Damon Runyon
-The V Foundation
-DoD
-Sontag Foundation
-Chenevert Foundation
-Pershing Square Sohn Cancer Research Alliance
-JDRF
-LRA
Latest Highlights
06/11/2026: Congrats to Alev Baysoy, Xiaolong Tian, Paul Renauer, Feifei Zhang and colleagues for their paper in Nature Biotechnology, titled “Large-scale, spatially resolved panoramic CRISPR screening in native tissue environments using Perturb-DBiT”!
06/01/2026: Congrats to Feifei Zhang, Chuanpeng Dong, Ryan D Chow, Shan Xin and colleagues for their paper in Cancer Discovery, titled “Rational design of immune gene therapy combinations via in vivo CRISPR activation screen of tumor microenvironment modulators”!
02/25/2026: Congrats to Luojia Yang, Paul Renauer, Lei Peng and colleagues for their paper in Nature, describing OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours!
02/03/2026: Congrats to Chuangpeng Dong, Feifei Zhang and colleagues for their paper in Cancer Immunology Research, describing TCPGdb: A Comprehensive T-cell Perturbation Genomics Database for the Identification of Critical T-cell Regulators!
Lab video
Sidi Chen Lab 